上海市广发律师事务所 关于洛阳新强联回转支承股份有限公司 2024 年年度股东大会的 法律意见书 电话：021-58358013 | 传真：021-58358012 网址：http://www.gffirm.com | 电子信箱：gf@gffirm.com 办公地址：上海市浦东新区南泉北路 429 号泰康大厦 26 楼 | 邮政编码：200120 上海市广发律师事务所 关于洛阳新强联回转支承股份有限公司 2024 年年度股东大会的法律意见书 致：洛阳新强联回转支承股份有限公司 洛阳新强联回转支承股份有限公司（以下简称"公司"）2024 年年度股东大 会于 2025 年 5 月 14 日在河南省洛阳市新安县新安经济技术开发区洛新园区京津 路 8 号 4 楼会议室召开。上海市广发律师事务所经公司聘请，委派藕淏律师、陈 雨兰律师出席现场会议，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《上市公司股东会规则》（以下简称"《股东会规则》"）等法律法规、其他规范性 文件以及《洛阳新强联回转支承股份有限公司章程》（以下简称"《公司章程》"） 的规定，就本次股东大会的召集和召开程序、召集人及出席会议人员的资格、 ...

回转支承专业制造 2.本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间： 证券代码：300850 证券简称：新强联 公告编号：2025-033 债券代码：123161 债券简称：强联转债 洛阳新强联回转支承股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东大会没有否决议案的情形。 （1）现场会议：2025 年 5 月 14 日（星期三）下午 14:30。 （2）网络投票：通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 5 月 14 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00；通过深圳证券交易所互 联网投票系统进行网络投票的具体时间为：2025 年 5 月 14 日 9:15-15:00。 2、现场会议地点：河南省洛阳市新安县经济技术开发区洛新园区京津路 8 号 4 楼 会议室。 3、会议的召开方式：本次股东大会采用现场表决与网络投票相结合的方式。 4、会议召集人：公司第四届董事 ...

Group 1: 华峰化学 - Company decided to terminate the acquisition of 100% equity in Zhejiang Huafeng Synthetic Resin Co., Ltd. and Zhejiang Huafeng Thermoplastic Polyurethane Co., Ltd. due to insufficient shareholder approval [1] - The decision was made based on prudence, as the proposal did not receive more than two-thirds of the valid voting rights at the shareholders' meeting [1] - Company will continue to promote related equity injection work and strictly fulfill asset injection commitments [1] Group 2: 中荣股份 - Actual controller and chairman Huang Huanran has been placed under residential surveillance by the police [2] - Other board members and senior management are performing their duties normally, and the board of directors is operating as usual [2] - Company specializes in the research, design, production, and sales of paper printing and packaging products [2] Group 3: 密尔克卫 - Three shareholders plan to reduce their holdings by a total of up to 2% of the company's shares through block trading [3] - The reduction includes 143.63 million shares, 97.65 million shares, and 75.03 million shares, representing 0.91%, 0.62%, and 0.47% of the total share capital respectively [3] - The reduction period is from June 6, 2025, to September 5, 2025, due to personal funding needs [3] Group 4: 舒泰神 - Subsidiary Jiangsu Beijietai Biotechnology Co., Ltd. has obtained a drug production license from the Jiangsu Provincial Drug Administration [4] - The license allows for the production of therapeutic biological products, specifically for registered declaration use [4] - The license is valid until May 7, 2030, and is not expected to have a significant impact on the company's current performance [4] Group 5: 捷顺科技 - Company won the bid for the "Chongqing Beautiful Sunshine Home and other public rental housing supporting parking space operation project" [5] - The project includes four public rental housing supporting parking lots with a total of 13,335 parking spaces [5] - The minimum guaranteed revenue for the project is quoted at 40.43 million yuan per year, with a total contract amount expected to exceed 100 million yuan [5] Group 6: 综艺股份 - Company signed an investment cooperation intention agreement to acquire control of Jiangsu Jilai Microelectronics Co., Ltd. through cash capital increase or share transfer [6] - Jilai Micro primarily engages in the research, production, and sales of power semiconductor chips and devices [6] - The transaction is expected to constitute a major asset restructuring [6] Group 7: 东山精密 - Subsidiary DSBJ PTE. LTD. plans to acquire 100% equity of French GMD Group for approximately 100 million euros (about 814 million yuan) [7] - The acquisition aims to advance the company's globalization strategy and enhance its market share in the automotive parts sector [7] - The company specializes in the research, production, and sales of electronic circuit products and precision components [7] Group 8: 诺诚健华 - Company reported a net profit of 17.97 million yuan for the first quarter of 2025, a significant turnaround from a loss of 142 million yuan in the same period last year [8] - The first quarter revenue reached 381 million yuan, representing a year-on-year growth of 129.92% [8] - The company focuses on the research, production, and commercialization of innovative drugs [8] Group 9: 凯美特气 - Shareholders plan to reduce their holdings by up to 3% of the company's shares through centralized bidding and/or block trading [9] - The total number of shares to be reduced is 20.86 million [9] - The reduction is due to personal funding needs [9] Group 10: 海创药业 - Controlling shareholder plans to reduce holdings by up to 2% of the company's shares through centralized bidding and block trading [10] - The total number of shares to be reduced is 1.98 million [10] - The reduction is due to personal funding needs [10] Group 11: 高争民爆 - Controlling shareholder plans to reduce holdings by up to 3% of the company's shares through centralized bidding and block trading [11] - The total number of shares to be reduced is 828,000 [11] - The reduction is due to the company's funding needs [11] Group 12: 金埔园林 - Two shareholders plan to reduce their holdings by a total of up to 1.91% of the company's shares [12] - The reductions include 183.93 million shares and 167.73 million shares [12] - The reasons for the reductions are asset optimization and personal funding needs [12] Group 13: 掌趣科技 - The largest shareholder plans to reduce holdings by up to 1% of the company's shares through centralized bidding or block trading [13] - The total number of shares to be reduced is 27.2 million [13] - The reduction is due to personal funding needs [13] Group 14: 美凯龙 - Company announced that its director and general manager has been placed under investigation and detention by the local supervisory committee [14] - Other board members and senior management are performing their duties normally, and daily operations are unaffected [14] - The company specializes in managing and operating self-operated and franchised shopping malls [14] Group 15: 新强联 - Major shareholder plans to reduce holdings by up to 1.89% of the company's shares through centralized bidding and block trading [15] - The total number of shares to be reduced is 717,490 [15] - The reduction is due to operational needs [15] Group 16: 日月明 - Shareholder plans to reduce holdings by up to 1% of the company's shares through centralized bidding [16] - The total number of shares to be reduced is 80,000 [16] - The reduction is due to personal funding needs [16] Group 17: 同有科技 - Major shareholder and vice president plan to reduce their holdings by up to 1.53% of the company's shares [17] - The total number of shares to be reduced is 730,850 [17] - The reduction is due to personal funding needs [17] Group 18: 爱尔眼科 - Subsidiary successfully acquired 60% equity and specific debt of Shenzhen Guangsheng Digital Technology Co., Ltd. for 650 million yuan [18] - The transaction constitutes a related party transaction [18] - The acquired asset will serve as long-term medical premises for the subsidiary [18]

恒邦股份：信息披露不及时，被出具监管函 雪榕转债，强联转债：不强赎 关注集思录微信 特别提示 金埔园林：股东拟减持不超1.91%公司股份 新强联：股东拟减持不超1.89%公司股份 快捷查询： 搜索公众号"jisilu8"添加我们 本文不构成任何投资建议，仅为信息分享。任何因本文导致的投资行为发生的亏损，本公众号 及作者概不承担任何责任。 集思录(www.jisilu.cn)是一个以数据为本的投资理财社区，专注于新股、可转债、债券、封闭 基金等数据服务。我们的理念是在保证本金安全的前提下，使资产获得稳健增长。 ...

新强联（300850）公告，持股5%以上股东海通开元计划在2025年6月5日至2025年9月4日期间，以集中 竞价和大宗交易方式减持不超过358.74万股，占公司总股本比例0.95%。 ...

回转支承专业制造 洛阳新强联回转支承股份有限公司 关于持股 5%以上股东减持股份预披露公告 大股东海通开元投资有限公司保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供 的信息一致。 特别提示： 持有洛阳新强联回转支承股份有限公司（以下简称"新强联"或"公司"）股份 2 2,912,097 股（占公司总股本比例 6.04%，以截至 2025 年 5 月 12 日的总股本 379,175, 746 股计算，下同）的大股东海通开元投资有限公司（以下简称"海通开元"）计划在 自本公告披露之日起 15 个交易日后的三个月内（2025 年 6 月 5 日至 2025 年 9 月 4 日） 以集中竞价方式减持本公司股份不超过 3,587,447 股（占公司总股本比例 0.95%）、以 大宗交易方式减持公司股份不超过 3,587,447 股（占公司总股本比例 0.95%）。 证券代码：300850 证券简称：新强联 公告编号：2025-032 债券代码：123161 债券简称：强联转债 （一）本次减持计划基本内容 1、本次拟减持的原因： ...

回转支承专业制造 证券代码：300850 证券简称：新强联 公告编号：2025-031 债券代码：123161 债券简称：强联转债 洛阳新强联回转支承股份有限公司 关于不提前赎回"强联转债"的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 特别提示： 自 2025 年 4 月 18 日至 2025 年 5 月 13 日，公司股票已满足任意连续三十个交易日 中至少十五个交易日的收盘价格不低于当期转股价格（21.89 元/股）的 130%（即 28.46 元/股），根据《洛阳新强联回转支承股份有限公司向不特定对象发行可转换公司债券 募集说明书》（以下简称"《募集说明书》"）中有条件赎回条款的相关规定，已触发 "强联转债"有条件赎回条款。 公司于 2025 年 5 月 13 日召开第四届董事会第十五次会议，审议通过了《关于不提 前赎回"强联转债"的议案》，公司董事会决议本次不行使"强联转债"的提前赎回权 利。同时，在未来三个月内（（即 2025 年 5 月 14 日至 2025 年 8 月 13 日），如再次触 发"强联转债"有条件赎回条款时，公司均不行使提前 ...

二、董事会会议审议情况 与会董事对需审议的议案进行了充分讨论，相关议案审议和表决情况如下： 回转支承专业制造 | 证券代码：300850 | 证券简称：新强联 | 公告编号：2025-030 | | --- | --- | --- | | 债券代码：123161 | 债券简称：强联转债 | | 洛阳新强联回转支承股份有限公司 第四届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 洛阳新强联回转支承股份有限公司（以下简称"公司"）第四届董事会第十五次会 议于 2025 年 5 月 13 日下午 15：00 以现场会议方式召开，现场会议的会议地点在公司 四楼会议室，本次会议通知于 2025 年 5 月 9 日以电话通知、电子通讯通知、专人通知 等方式送达全体董事。本次会议由公司董事长肖争强先生召集和主持，会议应到董事 6 人，实到 6 人，公司监事和高级管理人员列席了本次董事会。 本次会议的召集、召开程序符合有关法律、法规、部门规章、规范性文件和《公司 章程》的规定。 三、备查文件 《洛阳新强联回转支承股份有限公 ...

Group 1: Company Performance and Orders - The company expects its overall performance in 2025 to be influenced by industry conditions and downstream customer demand, with sufficient production orders currently in hand [2] - The company is experiencing strong demand in the wind power sector, which positively impacts its order situation [3] - The company has not disclosed specific order details through contract liabilities, but it confirms a robust order backlog [3] Group 2: Product Development and Technology - The company has achieved technological breakthroughs in wind turbine gearbox bearings and plans to complete the precision component project by June 2025 [3] - There are currently no plans to enter the humanoid robot bearing market, as the company's products are primarily focused on wind power and other heavy machinery [3][5] - The company is concentrating on high-end precision bearings in the wind power sector and has no immediate plans to develop products for other applications [5] Group 3: Stock and Market Management - The company's stock price is influenced by macroeconomic factors, market trends, and policy directions, with a focus on sustainable value creation for investors [4] - The management is committed to enhancing operational performance and maintaining effective communication with investors to improve market perception [4] Group 4: Production Capacity and Future Plans - Future capacity expansion will depend on industry conditions, customer demand, and the company's overall development strategy [3] - The company is currently maximizing production capacity through equipment upgrades and process optimization to meet customer delivery requirements [3]